Originally awarded in 1992, this application requests a five-year renewal of the T32 Head and Neck Training Program in Surgical Oncology at Memorial Sloan-Kettering Cancer Center (MSKCC). The mission of the Head and Neck T32 program is to train a highly selected group of talented head and neck oncologic surgeons to become high-caliber translational scientists and future academic leaders who will be positioned to advance the management of head and neck cancers. MSKCC, an NCI- designated comprehensive cancer center, provides a fertile environment rich in scientific and clinical resources that support intensive training in translational research. This T32's research training strategy integrates the following key components: (1) a committed and experienced Program Faculty spanning a wide range of scientific disciplines, with established track records of successful mentorship, (2) immersion into rigorous scientific research training in an R01-funded laboratory with appropriate guidance, (3) didactic research coursework, and (4) career development workshops. Each year, two new postdoctoral (MD or MD/PhD degrees) trainees are appointed to the Head and Neck T32 training grant for two contiguous years of dedicated research training. During this period, Head and Neck T32 trainees engage full-time in basic or translational mentored research related to head and neck cancers. Areas of potential research include genomics, molecular biology, cell biology, signal transduction, immunology, transgenic mouse modeling, chemoprevention, experimental therapeutics, and others. Research projects are matched to the particular academic interests and goals of the T32 trainee. Head and NeckT32 trainees will also enter a formal didactic program in head and neck oncology and research training, designed to supplement their individualized mentored research training. Career development workshops and seminars will help to prepare the T32 trainee for a successful competitive academic career. These workshops focus on grant writing skills, applying for career development awards, and developing the tools necessary for future independent research support. Head and Neck T32 trainees will be monitored closely and are expected to meet training milestones at designated time points. Specific expectations are delineated for trainee publications, grant submissions, national meeting presentations, and attendance at didactic conferences. Historically, a high proportion of trainees supported by the MSKCC Head and Neck T32 training program have entered academic head and neck surgical oncology and gone on to become prominent figures in the field, reflecting the effectiveness of this continuing program.

Public Health Relevance

Incidence rates for thyroid cancer and human papilloma virus (HPV)-related head and neck cancers are steadily rising, and tobacco-related head and neck cancers continue to be identified as a public health priority by the NIH. Research at the cellular, genetic, and molecular levels has revealed that cancers of the head and neck have a complex biology, distinct from other cancer types. The T32 Head and Neck Training Program in Surgical Oncology at MSKCC trains qualified clinician-scientists in head and neck cancer basic and translational research to specifically address these unique diseases.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA009685-22
Application #
8730083
Study Section
Subcommittee B - Comprehensiveness (NCI)
Program Officer
Lim, Susan E
Project Start
1992-08-01
Project End
2018-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
22
Fiscal Year
2014
Total Cost
Indirect Cost
City
New York
State
NY
Country
United States
Zip Code
10065
GarcĂ­a Nores, Gabriela D; Ly, Catherine L; Cuzzone, Daniel A et al. (2018) CD4+ T cells are activated in regional lymph nodes and migrate to skin to initiate lymphedema. Nat Commun 9:1970
Gardenier, Jason C; Kataru, Raghu P; Hespe, Geoffrey E et al. (2017) Topical tacrolimus for the treatment of secondary lymphedema. Nat Commun 8:14345
Lopez-Albaitero, Andres; Xu, Hong; Guo, Hongfen et al. (2017) Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody. Oncoimmunology 6:e1267891
Price, Daniel L; Li, Pingdong; Chen, Chun-Hao et al. (2016) Silk-elastin-like protein polymer matrix for intraoperative delivery of an oncolytic vaccinia virus. Head Neck 38:237-46
Deborde, Sylvie; Omelchenko, Tatiana; Lyubchik, Anna et al. (2016) Schwann cells induce cancer cell dispersion and invasion. J Clin Invest 126:1538-54
Gardenier, Jason C; Hespe, Geoffrey E; Kataru, Raghu P et al. (2016) Diphtheria toxin-mediated ablation of lymphatic endothelial cells results in progressive lymphedema. JCI Insight 1:e84095
Cracchiolo, Jennifer R; Roman, Benjamin R; Kutler, David I et al. (2016) Adoption of transoral robotic surgery compared with other surgical modalities for treatment of oropharyngeal squamous cell carcinoma. J Surg Oncol 114:405-11
Mandal, Rajarsi; Chan, Timothy A (2016) Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. Cancer Discov 6:703-13
Cracchiolo, Jennifer R; Baxi, Shrujal S; Morris, Luc G et al. (2016) Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base. Cancer 122:1523-32
Mandal, Rajarsi; ?enbabao?lu, Yasin; Desrichard, Alexis et al. (2016) The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight 1:e89829

Showing the most recent 10 out of 103 publications